Replies to post #81000 on Innovation Pharmaceuticals Inc (IPIX)

[TheMonolith]

The great thing about CTIX is that there are multiple irons in the fire. B is an entire platform with many possible uses for different indications. Hopefully, a partnership will be inked soon, and will de-risk the portfolio further. What many new people may not appreciate is the brilliance in which CTIX acquired B in a stalking horse bid for $5M and some stock. They went all-in for K, but happened to fall into B while nobody was watching. Re-tooled B, and now are getting great results. Dr. Menon has a track record with drug development. Leo is proving to be a great captain, running the show lean, mean, and with purpose.

[F1ash]

Well, up until today one of the biggest risks was that the whole thing could be a dog and pony show. No real products, or products rescued from the "trash heap". Much of that risk was reduced today and look what you get. They have three main drugs, all with completely different target markets. All could be first in class or best in class. Throw in a whole host of investigational compounds from the Polymedix purchase and you get lots and lots of reward for your risk.

[TheDane]

Welcome jsc!

[TOB]

Good to see you on the CTIX rocket ship jsc52033.

Right now the risk for CTIX is relatively low considering it is a start up bio-tech. The lowest since I've been watching it. (Hard to believe I can say this about a clinical stage bio-tech)

Future trials for all three main drug assets are all but certain. Each a potential share price rally or support agent pre-results, and then a catalyst for the results.

Once those trials are a go, there will be risk for each of them, but each of the three drugs provide safety nets for the other two. If just one makes it to approval it is a big win, they are all potential blockbusters. But before we get those results, there is much to argue for a higher share price.